Literature DB >> 12458405

Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies.

Michael D Devous1.   

Abstract

This review considers the role of functional brain imaging techniques in the dementias. The substantial assistance that especially single-photon emission tomography and positron emission tomography can play in the initial diagnosis of dementia and in the differential diagnosis of the specific dementing disorder is discussed. These techniques alone essentially match the sensitivity and specificity of clinical diagnoses in distinguishing Alzheimer's dementia (AD) from age-matched controls, from frontal lobe dementia and vascular dementia, and even from Lewy body dementia. Newer analytic techniques such as voxel-based correlational analyses and discriminant function analyses enhance the power of such differential diagnoses. Functional brain imaging techniques can also significantly assist in patient screening for clinical trials. The correlation of the observed deficits with specific patterns of cognitive abnormalities permits enhanced patient management and treatment planning and improved longitudinal assessment of outcome. It is also noteworthy that the classic abnormalities of temporoparietal and posterior cingulate hypoperfusion or hypometabolism appear to be present prior to symptom onset. These abnormalities predict progression to AD in the presence of the earliest of symptoms, and are present even in cognitively normal but at-risk subjects, with a severity proportional to the risk status. Even greater predictive ability for progression to AD is obtained by combining measures of perfusion or metabolism with risk factors, tau protein levels, hippocampal N-Acetyl aspartate concentrations, or hippocampal volume measures.

Entities:  

Mesh:

Year:  2002        PMID: 12458405     DOI: 10.1007/s00259-002-0967-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  27 in total

1.  Global cognitive impairment should be taken into account in SPECT-neuropsychology correlations: the example of verbal memory in very mild Alzheimer's disease.

Authors:  G Rodriguez; S Morbelli; A Brugnolo; P Calvini; N Girtler; A Piccardo; N J Dougall; K P Ebmeier; J C Baron; F Nobili
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06-02       Impact factor: 9.236

Review 2.  Positron emission tomography scans obtained for the evaluation of cognitive dysfunction.

Authors:  Daniel H S Silverman; Lisa Mosconi; Linda Ercoli; Wei Chen; Gary W Small
Journal:  Semin Nucl Med       Date:  2008-07       Impact factor: 4.446

3.  EANM procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals, version 2.

Authors:  Ozlem L Kapucu; Flavio Nobili; Andrea Varrone; Jan Booij; Thierry Vander Borght; Kjell Någren; Jacques Darcourt; Klaus Tatsch; Koen J Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

4.  Diagnosis of Alzheimer's disease using brain perfusion SPECT and MR imaging: which modality achieves better diagnostic accuracy?

Authors:  Takao Kubota; Yo Ushijima; Kei Yamada; Chio Okuyama; Osamu Kizu; Tsunehiko Nishimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-11-20       Impact factor: 9.236

5.  Joint analysis of structural and perfusion MRI for cognitive assessment and classification of Alzheimer's disease and normal aging.

Authors:  Duygu Tosun; Pouria Mojabi; Michael W Weiner; Norbert Schuff
Journal:  Neuroimage       Date:  2010-04-18       Impact factor: 6.556

6.  Transcranial doppler ultrasound blood flow velocity and pulsatility index as systemic indicators for Alzheimer's disease.

Authors:  Alex E Roher; Zsolt Garami; Suzanne L Tyas; Chera L Maarouf; Tyler A Kokjohn; Marek Belohlavek; Linda J Vedders; Donald Connor; Marwan N Sabbagh; Thomas G Beach; Mark R Emmerling
Journal:  Alzheimers Dement       Date:  2011-03-09       Impact factor: 21.566

Review 7.  Brain hypometabolism triggers PHF-like phosphorylation of tau, a major hallmark of Alzheimer's disease pathology.

Authors:  Thomas Arendt; Jens Stieler; Max Holzer
Journal:  J Neural Transm (Vienna)       Date:  2014-12-06       Impact factor: 3.575

8.  Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease.

Authors:  Montse Alegret; Mercè Boada-Rovira; Georgina Vinyes-Junqué; Sergi Valero; Ana Espinosa; Isabel Hernández; Gemma Modinos; Maitee Rosende-Roca; Ana Mauleón; James T Becker; Lluís Tárraga
Journal:  J Clin Exp Neuropsychol       Date:  2009-01-14       Impact factor: 2.475

Review 9.  Imaging markers for Alzheimer disease: which vs how.

Authors:  Giovanni B Frisoni; Martina Bocchetta; Gael Chételat; Gil D Rabinovici; Mony J de Leon; Jeffrey Kaye; Eric M Reiman; Philip Scheltens; Frederik Barkhof; Sandra E Black; David J Brooks; Maria C Carrillo; Nick C Fox; Karl Herholz; Agneta Nordberg; Clifford R Jack; William J Jagust; Keith A Johnson; Christopher C Rowe; Reisa A Sperling; William Thies; Lars-Olof Wahlund; Michael W Weiner; Patrizio Pasqualetti; Charles Decarli
Journal:  Neurology       Date:  2013-07-30       Impact factor: 9.910

Review 10.  [PET and SPECT investigations in Alzheimer's disease].

Authors:  S Asenbaum
Journal:  Radiologe       Date:  2003-06-25       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.